BUZZ-Aeterna Zentaris Inc: Committee recommends late-stage trial continue
** Canadian drug developer's U.S.-listed shares up 15 pct at 9 cents
** Aeterna says an independent data and safety monitoring committee recommended it continue testing its endometrial cancer drug in a late-stage study
** The drug, zoptarelin doxorubicin, is being tested in women with advanced, recurrent or metastatic endometrial cancer; drug is also being evaluated for use in ovarian and prostate cancer
** If all goes well, the drug could become the first FDA-approved therapy for the condition, company says
** There will be about 50,000 new cases of endometrial cancer in the U.S. in 2015, about 20 pct of which will recur, the American Cancer Society estimates
** Up to Monday's close, U.S.-listed stock had risen about 87 pct this year
© Thomson Reuters 2017 All rights reserved.